Journal of the European Academy of Dermatology and Venereology
| Autor: | Arellano, I., Cestari, Tania Ferreira, Candiani, J. Ocampo, Abulafia, L. Azulay, Trindade Neto, Pedro Bezerra da, Hexsel, Doris Maria, Pinto, J. Machado, Muñoz, H., Machado, Maria Cecilia da Matta Rivitti, Sittart, José Alexandre de Souza, Almeida, A. R. Trindade de, Rego, V., Paliargues, F., Hassun, K. Marques |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Zdroj: | Repositório Institucional da UFBA Universidade Federal da Bahia (UFBA) instacron:UFBA |
| DOI: | 10.1111/j.1468-3083.2011.04135.x |
| Popis: | Texto completo: acesso restrito. p. 611–618 Submitted by Edileide Reis (leyde-landy@hotmail.com) on 2014-08-11T14:19:34Z No. of bitstreams: 1 V. Rego.pdf: 524299 bytes, checksum: ebaf1d816cad38d17afebe4f1fd47f81 (MD5) Approved for entry into archive by Delba Rosa (delba@ufba.br) on 2014-10-09T16:09:03Z (GMT) No. of bitstreams: 1 V. Rego.pdf: 524299 bytes, checksum: ebaf1d816cad38d17afebe4f1fd47f81 (MD5) Made available in DSpace on 2014-10-09T16:09:03Z (GMT). No. of bitstreams: 1 V. Rego.pdf: 524299 bytes, checksum: ebaf1d816cad38d17afebe4f1fd47f81 (MD5) Previous issue date: 2012 Background The relapsing nature of melasma emphasizes the need to maintain efficacy achieved after acute treatment. Objective To compare clinical efficacy and safety of two 6-month Triple Combination (TC; containing fluocinolone acetonide, hydroquinone and tretinoin) maintenance regimens in subjects with moderate to severe melasma, after daily treatment up to 8 weeks. Methods This randomized, investigator-blinded, controlled study had a maintenance phase of 6 months. Sixteen centres in Brazil and Mexico enrolled 242 subjects 18 years or older attaining no or mild melasma after 8 weeks of daily TC applications. Subjects were randomized to receive TC in a twice weekly or tapering regimen [3/week (1st month), 2/week (2nd month), 1/week (4th month)]. Efficacy and safety measurements included median time to relapse and relapse-free rate, Global Severity Score, Melasma Area and Severity Index score (MASI), subject’s assessment, quality of life questionnaire (MelasQol), and adverse events. Results The majority (78.8%) had no or mild melasma (GSS ≤ 1) at week 8 and entered maintenance phase. After 6 months, 53% of patients remained relapse-free with improved quality of life, and time to relapse was similar between groups (about 190 days). Melasma severity at study entry, not maintenance baseline, influenced relapse rate. The twice weekly regimen tended to show better effectiveness in postponing relapse in severe melasma. Both regimens were safe. Conclusions After resolution of melasma with TC, maintenance therapy over 6 months was successful in preventing relapse in over half of the patients who entered maintenance phase. Prescribing medicines should be adapted to patients based on melasma severity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|